Based on the IGF-1 stimulatory effects, three RCC lines (Caki-2, ACHN, and 786-O) were selected for further testing for anti-IGF-1R-mediated growth-inhibition (Figure 3B). The gene discussed is IGF1; the disease is renal cell carcinoma.